INTRODUCTION
Von Recklinghausen neurofibromatosis (NFl) is one of the most common inherited disorders in humans, with an incidence of about 1 in 3000, and affecting all ethnic groups (Crowe et al., 1956; Riccardi, 1981; Riccardi and Eichner, 1986) . The spontaneous mutation rate is very high, with 3040% of cases being new mutations. This leads to a calculated mutation rate of l/10,000, which is about loo-fold higher than the usual mutation rate for a single locus.
The clinical features of the disorder can be quite variable, even among affected family members, indicating that factors other than the specific mutation inherited must play a role in the disease phenotype. Diagnostic criteria for NFl have been established (Stumpf et al., 1987) and with careful examination it is rare to identify an obligate carrier who does not meet these criteria (Riccardi and Lewis, 1988) . Diagnostic features include cafe-au-lait spots, Lisch nodules, and neurofibromas in the majority of gene carriers. Some individuals may also have learning disorders, more deeply placed plexiform neurofibromas, seizures, or skeletal abnormalities. The risk of malignancy is also increased, especially for optic glioma, neurofibrosarcoma, and brain tumors.
Recently, a gene was identified by positional cloning showing mutations in individuals affected with NFl (Cawthon et CLZ., 1990a; Wallace et al., 1990) . Further cloning and partial sequence analysis demonstrated that the gene product contains a domain showing approximately 30% similarity to the catalytic domains of yeast IRA1 and IRA2 proteins and the mammalian GTPase activating protein (GAP) (Xu et al., 1990a) . GAP is a cytosolic protein that catalyzes the conversion of active GTP-bound ras p21 to the inactive GDP-bound form (Trahey and McCormick, 1987; Trahey et al., 1988; Vogel et uZ., 1988) . The IRA genes of Saccharomyces cerevisiae encode negative regulators of the yeast RAS genes that are homologs of mammalian GAP (Tanaka et uZ., 1989, 1990, 1991) . It was subsequently shown that the GAP-related domain of the NFl gene product can also interact with human and yeast ~(2s p21 to down-regulate its activity (Ballester et cd., 1990; Martin et UC, 1990; Xu et al., 199Ob) .
Previous reports of cDNA cloning of NFl were based on incomplete fragments of the transcript, which is approximately 13 kb by Northern blotting (Wallace et uZ., 1990) . In this report we present the complete amino acid sequence of the NFl gene product as deduced from cDNA clones containing the entire coding region of the gene. The location and extent of the NFl gene on the genomic map of chromosome 17 is also determined.
MATERIALS AND METHODS

Isolation of NFl cDNA Clones
Five different cDNA libraries were used in the cDNA walk. A human fetal brain cDNA library, ). An oligo d(T) primed human fetal muscle library is described in Koenig et ~2. (1987) , and a random primed endothelial cell library is described in Ginsburg et al. (1985) . Typically, 500,000 plaques of each library were plated and screened (Benton and Davis, 1977) using an aqueous hybridization consisting of 6X SSC, 2~ Denhardt's solution, 1 mM EDTA, and 0.5% SDS at 65°C. Washes were in 2X, 1X, and if needed, 0.2~ SSC, 0.1% SDS at 65°C. Positive plaques were purified, and subcloned into Bluescript plasmid (Stratagene) or rescued as plasmid per X ZAP instructions (Stratagene) in the case of the fetal brain library.
Sequence Analysis of Clones Double-stranded sequencing of plasmid clones was performed using Sequenase Version 2.0 (U.S. Biochemicals, Cleveland, OH) per instructions. Sequence compilation was aided by the IBI/Pustell sequence analysis program package (International Biotechnologies, Inc., New Haven, CT). Analysis of the amino acid sequence was performed with the University of Wisconsin Genetics Computer Group protein analysis package (Devereux et aZ., 1984) .
Primer Extension
Total RNA was isolated from fresh human brain (frontal lobe) and melanoma cell line SK-MEL-23 (Carey et al., 1976) as described in Sambrook et al. (1989) . Polyadenylated RNA was isolated from melanoma total RNA using the FastTrack mRNA isolation kit (Invitrogen Corp., San Diego, CA). For primer extension, an oligomer (5' AGAGGCAAGGA-GAGGGTCTGTG) was synthesized, kinased with 32P and extended off of brain (total) or melanoma (poiy(A)+) RNA (Boorstein and Craig, 1989) . Products were analyzed on a 6% denaturing polyacrylamide gel. Figure 1 shows a cDNA walk extending from the 3' end of the NFl gene. The initial clones P5 and B3A were isolated as previously described (Wallace et al., 1990) . Since the NFl transcript has been shown to be ubiquitously expressed (Buchberg et aZ., 1990; Wallace et al., 1990) , cDNA walking proceeded in multiple cDNA libraries in order to maximize chances of finding positives. Library sources included fetal muscle, (65)). The sequence was compiled from clones KE-2, GE-2, GMSA, EF2, FF13, and HFBA. Both strands were sequenced at least once to complete the sequence. The nucleotide and deduced amino acid sequence are numbered along the left column.
RESULTS
The start codon is underlined, and the upstream in-frame stop codon is boxed. The position of the oligonucleotide used for primer extension ( Fig. 3 ) is shown by an arrow. The position of the first intron is indicated by a triangle. fetal brain, adult brain (occipital pole and medulla), and endothelial cells. Walks proceeded sequentially by isolation of positive phage clones using the most 5' cDNA insert. The positive clones were characterized by restriction mapping using EcoRI and Southern blot analysis using previously isolated inserts. The phage clones were subcloned into Bluescript (Stratagene) and the ends were sequenced to anchor the position of the clones to the transcript map. The cycle was repeated for each walk. Underrepresented regions in any given library were overcome by crossing into another library. The entire transcript as represented in the clones was sequenced multiple times and both strands were sequenced at least once for all previously unpublished sequence. As the cDNA walk neared completion, a very GCrich region of the transcript that contained an abnormally high concentration of the dinucleotide CpG, as well as rare cutting restriction endonuclease sites EogI, NurI, and SucII, was encountered at the 5' end. These sites had been previously placed on the pulsedfield map of this region using the linking clone 17Ll (Fountain et al., 1989a) . This clone was isolated from a Not1 linking library constructed from DNA from flow-sorted chromosome 17 (Wallace et al., 1989) , and contains the sequences flanking both sides of a genomic Not1 site. This probe was originally used to detect a translocation breakpoint within the NFl gene, which narrowed the search for the gene to a region of only about 300 kb (Fountain et al., 198913) . Southern blots using the CpG-rich cDNAs as probes against 17Ll demonstrated that the most 5' sequences obtained were indeed located in the centromeric half of this clone (17LlB), approximately 300 kb from the 3' stop codon (data not shown).
The most 5' cDNA clone, KR-2, isolated from the endothelial cell cDNA library, contained an in-frame stop codon (Fig. 2) . Downstream from this stop codon, the first ATG fits the rules for a proper translational start (Kozak, 1986) . Overlapping sequences have been found in cDNA clones from three different tissues (fetal muscle, fetal brain, and endothelial cells). We propose that this ATG codon represents the authentic start codon, giving the protein a total of 2818 amino acids with a predicted molecular weight of 327 kDa.
To determine whether a substantial portion of the 5' end of this transcript remained uncloned, a primer extension was performed using human brain (frontal lobe) total RNA and melanoma cell line SK-MEL-23 poly(A)+ RNA. A reverse transcription primer was chosen that was 5', of the proposed start codon. Figure  3 shows the result of this analysis. A series of four bands ranging in size from 380 to 410 bp is seen in the primer extension from brain RNA. A second prominent band of 300 bp is also seen. Primer extension from the melanoma RNA shows the top two bands at 400 and 410 bp, but does not show the lower band at 300 bp. We have cloned and sequenced 119 bp from the 5' position of this primer, indicating that at most only 291 bp remains uncloned. Within the cloned sequence lies the start codon and upstream in-frame stop codon. These results indicate that the entire coding region of the transcript has been cloned and sequenced.
Sequencing of the proximal half of the Not1 linking clone 1'7Ll (17LlB) demonstrated that the 5' cDNA sequences from nucleotide 1 to 270 exist in this region of the genome as a single continuous exon. We conclude from this that exon 1 of this transcript contains a majority of sequence that is 5' untranslated.
If another exon is spliced in upstream from this, it would consist entirely of noncoding sequence. We also conclude that the transcriptional start site and the promoter region probably exist in the half linking clone 17LlB.
In the course of screening for cDNA clones that extended beyond our most 5' clone, two alternative sequences were discovered.
Both begin at position 270, the position of the first splice junction, and are represented by single cDNA clones from a fetal brain cDNA library. Further analysis of these clones has revealed that neither represent authentic NFl mRNA. One sequence appeared to be derived from an unspliced message, as it contains a perfect splice-acceptor consensus sequence, a pyrimidine stretch of 20 bases, and a lariat formation consensus sequence (Sharp, 1987) . This has been confirmed by designing primers that extend across the splice junction and by showing that these primers will amplify the expected fragment using genomic DNA as a template (data not shown). A second unusual clone diverges at the exact same position, yet has a different sequence. This clone has been shown to be the result of a rare transsplicing event since the new sequence does not map to chromosome 17. We therefore conclude that there is no evidence for alternative splicing at the extreme 5' end of the gene.
We have been unable to characterize the 3' end of the NFl transcript, as a poly(A) tail has not been found in any cDNA clone. Our previous sequence analysis (Wallace et aZ., 1990) has shown the proper position of the stop codon. Downstream from this the sequence is very A rich, with some regions that are capable of priming with oligo(dT) during construction of the cDNA libraries. The NFl transcript has been estimated to be 13 kb by its migration on a Northern blot (Wallace et al., 1990) . To date we have cloned and sequenced 9 kb of this message. The primer extension results (Fig. 3) indicate that the majority of uncloned sequence from this transcript must arise from a long (approximately 4 kb) 3' untranslated region. Alternatively, our estimates of transcript size may be incorrect, as size estimates in this range of Northern blotting are difficult.
Two alternatively processed forms of this primary transcript have been discovered. A 54-bp insertion coding for an additional 18 amino acids near the 3' end of the transcript has been described previously . A 63-bp insertion coding for an additional 21 amino acids within one of the most con- served regions of the GAP-related domain has been discovered ( Fig. 4 ; Andersen et al., manuscript in preparation). The significance of this insertion to the ras GTPase activation will be discussed elsewhere. Figure 4 shows the complete amino acid sequence of the primary NFl transcript.
Boxed areas indicate the three blocks of homology most conserved between the GAP family of proteins (Wang et al., 1991) . The positions of the alternatively spliced exons,and their sequence are shown. There are no SH2 or SH3 domains (src homology domains), which are present in GAP (Koch et aZ., 1991) . The protein shows no apparent membrane-spanning region and is predicted to be cytosolic by discriminant analysis (Klein et al., 1985) . A potential leucine zipper is present beginning at amino acid residue 1834, but this region is not predicted to be in an a-helical conformation due to the presence of a proline in the middle of the repeat. Six potential CAMP-dependent protein kinase phosphorylation sites and a single potential tyrosine phosphorylation 64,65)).
The three genes are EVISA (Refs. (38,13) ), EVIQB (Ref. (14)), and OMgp (Refs. (34,59) ).
site are present. The sequence shows no significant homology to the recently described &r-related GAP family, which includes n-chimaerin, and GAPrh" (Diekmann et al., 1991) and possibly the ~85 of bovine brain phosphatidylinositol 3-kinase (Otsu et aZ., 1991). There is also no homology to the recently described raplGAP (Rubinfeld et 'al., 1991) .
The size of the NFl gene has been determined by mapping cDNA clones back to the pulsed-field restriction map of the region (Fountain et al., 1989a) . The 5' end is just beyond the Not1 site within the linking clone 17LlB, the first intron beginning 81 bp centromerit to the Not1 site. The most 3' clone we have isolated does not extend beyond the Not1 site defining the next CpG island, and defines a maximum gene size of approximately 300 kb (Fig. 5) . This assumes that the remainder of the 3' untranslated region yet uncloned exists in a single exon. We have not characterized all of the intron-exon borders of the gene, but would estimate by the number of bands on a genomic Southern blot that it contains in excess of 30 exons. The three previously described embedded genes (EVI2A, EVIBB, and OMgp) are transcribed from the opposite strand and are contained within a single in- could stimulate ras-GTPase activity in uiuo and in vitro (Ballester et al., 1990; Martin et aZ., 1990; Xu et al:, 1990b) . We propose that the NFl gene product be named the NF1-GAP-related protein (NFlGRP; Gutmann et al., 1991 ).
An alternate model of ras-NFlGRP interaction postulates that NFlGRP may instead (or in addition) be a downstream effector for ras. A downstream model has also been proposed for the related GAP. Mutations in the putative rus effector domain inactivate the transforming ability of ras and block GTPase activation by GAP, yet retain guanine nucleotide binding capacity (Adari et al., 1988; Cales et al., 1988) . NFl -GRD interactions with effector and oncogenic mutants of m-s have shown similar results, suggesting that NFlGRP may also interact with ros p21 through its effector domain and be a target of activated ra (Martin et aZ., 1990; Xu et al., 1990b; Bollag and McCormick, 1991) . It should be cautioned, however, that none of these studies were done using full-length NFlGRP.
Nonetheless, the downstream effector model is attractive for its ability to account for the role of ras in certain cells of neuroectodermal origin. In the rat pheochromocytoma cell line PC12, activated ras induces differentiation and blocks proliferation (BarSagi and Feramisco, 1985; Noda et uZ., 1985) . Inhibition of ras in these cells blocks neural differentiation normally induced by nerve growth factor (Hagag et al., 1986; Szeberenyi et al., 1990) . Activated ras has also been shown to induce cell cycle arrest when introduced into rat Schwann cells (Ridley et cd., 1988) . This is significant because Schwann cells may be the original cells that recruit other cell types in the formation of neurofibromas and neurofibrosarcomas (Ratner et uZ., 1990; Sheela et al., 1990) . Therefore, if
NFlGRP is the target (effector) of ras, then loss of NFlGRP function could lead to a block of normal differentiation resulting in unrestrained proliferation of Schwann cells. Either of these two models, with NFlGRP as the upstream negative regulator or downstream effector, are consistent with NFl being a tumor suppressor gene, where the phenotype results from the loss of both alleles of the gene (Knudson, 1985) . Previous studies of NFl tumors did not show a consistent loss of heterozygosity for NFl in 17q11.2 (Skuse et al., 1989; Menon et al., 1990; Glover et al., 1991) , but these interpretations were made difficult by frequent losses on 17p, apparently reflecting the major role that loss of the ~53 gene plays in tumor progression in this disorder (Nigro et al., 1989; Menon et al., 1990) . More recent analyses have indicated that loss of heterozygosity involving only 17q can be demonstrated at least for some tumors (Skuse, 1990 ; E. Legius and T. Glover, personal communication; B. Ponder, personal communication) .
The large NFl transcript and 300-kb gene size represent a large target for mutations. Assuming that the NFl phenotype results from loss of function mutations, causative mutations may be dispersed throughout the coding and regulatory region. In the patients surveyed thus far, this seems to be the case (Cawthon et al., 1990a; Wallace et al., 1990 ; M. Wallace et al., unpublished observations). The size of the gene alone, however, cannot fully account for the high mutation rate. At best, the possible target size is only a factor of 10 larger than other genes, whereas the mutation rate is about loo-fold higher than the usual rate for a single locus. There is presently not enough mutation data to determine whether there is a mutational hot spot within this region.
The complete sequence of the NFl gene product has provided few additional clues to its function. The lack of SH2 and SH3 domains are in contrast to GAP. Homologous to noncatalytic regions of the oncogene src, these domains are thought to direct interactions with phosphotyrosine proteins involved in signal transduction (Koch et al., 1991) . Their absence in NFlGRP implies that NFlGRP and GAP are not interchangeable in the cell, and that NFlGRP is probably not directly modulated through tyrosine phosphorylation by activated growth factor receptors. The potential sites for tyrosine and serinelthreonine phosphorylation (Fig. 4) may mean that an intermediate between the activated receptor and NFlGRP may modulate its activity, since there is evidence that NFlGRP is phosphorylated on serine and threonine residues (J. Downward, personal communication). A potential candidate for this intermediate could be one of the members of the ERK family, which are activated by tyrosine phosphorylation by nerve growth factor and are themselves serine/threonine protein kinases (Boulton et al., 1991) . Certainly, the large size of the product in relation to the small portion conferring GAP activity indicates that other domains may be involved in modulating the ras-GTPase activity of this protein, or carrying out entirely different func-MARCHUK ET AL.
tions. The sequence homology with yeast IRA1 and IRA2 (Table 1) extends beyond the GAP catalytic domain toward both termini, with strong homology in the carboxy terminus. The homology, both globally and within each domain, is most significant with the IRA2 protein. There may be therefore more extensive functional homology with these members of the GAP family than with GAP itself. It may be useful to think of the NFlGRP as consisting of three domains; an amino-terminus of unknown function, a GAP-related middle domain, and a carboxy-terminus related to the IRA2 and IRA1 gene products. Unfortunately, the functions of these domains of the IRA gene products are not known even in this simple eukaryote. For NFlGRP, interaction with other factors in the pathway leading to differentiation, such as the low-affinity nerve growth factor receptor and the trk oncogene product, or factors that mediate between these and NFlGRP, may be localized to these yet undefined regions. Interactions at these other domains may also ultimately provide a clue as to the reasons why a mutation in a ubiquitously expressed gene reveals its character predominantly in cells derived from the embryonic neural crest.
It is presently unclear how the alternatively spliced transcripts and the corresponding protein isoforms play their unique role in NFlGRP function. We have not yet conducted an exhaustive search of the tissues where each of these transcripts can be found. We know that at least in some tissues, however, their expression is not mutually exclusive. These alternative forms may play a role in the diverse clinical manifestations of the disorder. Germline mutations in some of the alternatively spliced exons may give rise to some of the more unusual NFl phenotypes.
